# A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)

> **NCT05462106** · PHASE1,PHASE2 · RECRUITING · sponsor: **AC Immune SA** · enrollment: 176 (estimated)

## Conditions studied

- Amyloid Plaque
- Beta-Amyloid
- DSAD
- Prodromal Alzheimer's Disease
- Alzheimer's Disease

## Interventions

- **BIOLOGICAL:** Placebo
- **BIOLOGICAL:** ACI-24.060 at Dose A
- **BIOLOGICAL:** ACI-24.060 at Dose B
- **BIOLOGICAL:** ACI-24.060 at Dose C
- **BIOLOGICAL:** ACI-24.060 at Dose D
- **BIOLOGICAL:** Placebo
- **BIOLOGICAL:** ACI-24.060 at Dose A
- **BIOLOGICAL:** ACI-24.060 at Dose B
- **BIOLOGICAL:** ACI-24.060 at Dose C

## Key facts

- **NCT ID:** NCT05462106
- **Lead sponsor:** AC Immune SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-06-21
- **Primary completion:** 2026-06
- **Final completion:** 2026-06
- **Target enrollment:** 176 (ESTIMATED)
- **Last updated:** 2025-12-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05462106

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05462106, "A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05462106. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*